Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07382752
Decoupling Immunotherapy Toxicity and Cancer Response
Sponsor: M.D. Anderson Cancer Center
View on ClinicalTrials.gov
Summary
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
Official title: Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1200
Start Date
2026-01-09
Completion Date
2030-06-30
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Locations (1)
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States